University Hospital Heidelberg-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2022

  1. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

    Blood Advances, Vol. 6, Núm. 2, pp. 690-703

  2. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Journal of Clinical Oncology, Vol. 364

2019

  1. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312

  2. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469

2018

  1. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project

    Blood Cancer Journal, Vol. 8, Núm. 12

2017

  1. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Revised international staging system for multiple myeloma: A report from international myeloma working group

    Journal of Clinical Oncology, Vol. 33, Núm. 26, pp. 2863-2869

  2. Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement

    Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 657-664

2014

  1. Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death

    Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180

2013

  1. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: A meta-analysis of phase III randomized, controlled trials

    Journal of Clinical Oncology, Vol. 31, Núm. 26, pp. 3279-3287

  2. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project

    Leukemia, Vol. 27, Núm. 3, pp. 711-717